MicroVision's shares dropped 21.1% as investors reacted negatively to what appears to be cautious, early-stage commercial traction and integration progress, with no clear evidence of meaningful revenue acceleration or margin improvement to justify the stock prior to scaling.

• Q1 marked the start of commercial revenue but no specific figures or guidance upgrades were provided to signal acceleration.
• Integration of Luminar and Scantinel assets completed operationally, though benefits remain largely aspirational with product portfolio breadth emphasized over near-term sales impact.
• Shipments have restarted in industrial markets, and repeat orders continue, yet these appear modest and early in their ramp phases.
• Management highlighted progress and confidence, but refrained from updating growth or margin outlook, underscoring ongoing execution risks.
• Market reaction signals investor skepticism around the pace at which the combined technologies will translate into sustainable commercial and financial performance.